Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Target Price at $48.38

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $48.38.

TARS has been the topic of several recent research reports. Jefferies Financial Group raised their price target on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Oppenheimer restated an “outperform” rating and set a $59.00 target price (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 28th. Barclays boosted their target price on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 28th. Lifesci Capital reiterated an “outperform” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, December 26th. Finally, The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a “neutral” rating in a report on Thursday, February 29th.

Insider Activity

In related news, insider Aziz Mottiwala sold 4,766 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $145,839.60. Following the completion of the sale, the insider now directly owns 54,075 shares of the company’s stock, valued at approximately $1,654,695. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the transaction, the general counsel now owns 40,951 shares in the company, valued at approximately $1,253,100.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Aziz Mottiwala sold 4,766 shares of Tarsus Pharmaceuticals stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $145,839.60. Following the completion of the sale, the insider now directly owns 54,075 shares in the company, valued at approximately $1,654,695. The disclosure for this sale can be found here. Insiders have sold 24,496 shares of company stock worth $749,578 in the last 90 days. Corporate insiders own 11.54% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. RTW Investments LP boosted its position in Tarsus Pharmaceuticals by 9.4% during the 4th quarter. RTW Investments LP now owns 3,152,341 shares of the company’s stock worth $63,835,000 after acquiring an additional 271,640 shares during the last quarter. BlackRock Inc. boosted its holdings in Tarsus Pharmaceuticals by 51.0% during the second quarter. BlackRock Inc. now owns 2,199,753 shares of the company’s stock worth $39,750,000 after purchasing an additional 742,493 shares during the last quarter. Vanguard Group Inc. grew its position in Tarsus Pharmaceuticals by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,595,501 shares of the company’s stock valued at $32,309,000 after purchasing an additional 43,699 shares in the last quarter. TFG Asset Management GP Ltd increased its stake in Tarsus Pharmaceuticals by 30.1% in the 4th quarter. TFG Asset Management GP Ltd now owns 800,000 shares of the company’s stock valued at $16,200,000 after buying an additional 185,000 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at $13,399,000. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $32.44 on Thursday. The company has a market cap of $1.11 billion, a PE ratio of -6.99 and a beta of 1.05. The company has a current ratio of 6.93, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. Tarsus Pharmaceuticals has a 1 year low of $12.57 and a 1 year high of $40.40. The company’s 50-day moving average is $33.83 and its two-hundred day moving average is $24.37.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.06. The business had revenue of $13.08 million for the quarter, compared to the consensus estimate of $4.63 million. During the same period last year, the firm earned ($0.49) earnings per share. Equities analysts anticipate that Tarsus Pharmaceuticals will post -4.25 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.